Palonosetronhydrochlorid Qilu

Palonosetron, the active ingredient in Palonosetronhydrochlorid Qilu, is a selective 5-HT3 receptor antagonist presented as a sterile injectable solution for intravenous use. It is used to prevent chemotherapy‑induced nausea and vomiting in adult cancer patients. GNH USA supplies Palonosetronhydrochlorid Qilu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and oncology centres worldwide.

GNH USA supplies Palonosetronhydrochlorid Qilu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and oncology centres worldwide.

Palonosetron is a 5‑HT3 receptor antagonist indicated for prevention of nausea and vomiting associated with chemotherapy and surgery.

- Chemotherapy‑induced nausea and vomiting (CINV): helps prevent acute and delayed episodes in adult patients receiving highly emetogenic chemotherapy. - Post‑operative nausea and vomiting (PONV): reduces incidence of nausea and vomiting after general anesthesia. - Radiotherapy‑induced nausea and vomiting: mitigates nausea associated with high‑dose radiation therapy. - Antiemetic prophylaxis in stem‑cell transplantation: provides nausea control during conditioning regimens. - Nausea associated with opioid therapy: lessens nausea in patients receiving strong opioids. - Antiemetic support for patients receiving multiple‑day chemotherapy protocols.

Palonosetron is generally well‑tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: transient bowel habit changes. - Fatigue: general tiredness without specific cause. - Dizziness: occasional light‑headed sensation. - Injection site erythema: mild redness at the infusion site.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe hypersensitivity: rash, pruritus, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Cardiac arrest: extremely rare, reported in isolated cases. - Persistent vomiting despite therapy: may indicate inadequate response.

Before administering Palonosetron, consider the following safety measures.

- Cardiac assessment: evaluate baseline ECG in patients with known QT prolongation risk. - Concomitant serotonergic drugs: avoid or monitor for serotonin syndrome. - Electrolyte balance: correct hypokalemia, hypomagnesemia, or hypocalcemia before use. - Pregnancy and lactation: use only if clearly needed. - Renal or hepatic impairment: dose adjustment may be required; monitor liver function tests. - Store at ambient temperature: keep in original packaging, protect from moisture.

Palonosetron may interact with several drug classes; monitoring is advised.

Major Interactions (Avoid): - Other 5‑HT3 antagonists: concurrent use can increase risk of cardiac effects. - QT‑prolonging agents: additive risk of arrhythmia, especially in patients with cardiac disease.

Moderate Interactions (Monitor Closely): - Serotonergic agents (e.g., SSRIs, MAO inhibitors): may increase risk of serotonin syndrome. - CYP3A4 inhibitors/inducers: may alter palyto‑exposure levels, requiring observation. - Anticholinergic drugs: may affect gastrointestinal motility and nausea control. - Diuretics causing electrolyte loss: monitor electrolytes to reduce QT risk.